Tesch Hans, Müller Volkmar, Wöckel Achim, Ettl Johannes, Belleville Erik, Schütz Florian, Hartkopf Andreas, Thill Marc, Huober Jens, Fasching Peter A, Kolberg Hans-Christian, Schulmeyer Carla E, Welslau Manfred, Overkamp Friedrich, Fehm Tanja N, Lux Michael P, Schneeweiss Andreas, Lüftner Diana, Janni Wolfgang
Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany.
Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.
Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a mutation. The treatment of patients with a or mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.
近年来，能够干预特定信号通路且疗效良好的物质在晚期乳腺癌患者的治疗中越来越多地被使用，现在又增加了新的疗法和方法，这些实际上与相当具体的变化有关，例如对HR+/HER2肿瘤且有特定突变的患者进行治疗。PARP抑制剂的引入也改善了对有特定突变患者的治疗。现在越来越多地尝试根据分子模式扩大治疗适应症，确定其他可能从治疗中获益的患者，并将新建立的治疗方法纳入现有的治疗序列中。这篇综述文章总结了这方面的最新信息。
